PMID- 36401276
OWN - NLM
STAT- MEDLINE
DCOM- 20221128
LR  - 20221128
IS  - 2662-7671 (Electronic)
IS  - 2662-7671 (Linking)
VI  - 22
IP  - 1
DP  - 2022 Nov 18
TI  - Antioxidant and anti-inflammatory activities of Centratherum anthelminticum (L.) 
      Kuntze seed oil in diabetic nephropathy via modulation of Nrf-2/HO-1 and NF-kappaB 
      pathway.
PG  - 301
LID - 10.1186/s12906-022-03776-x [doi]
LID - 301
AB  - BACKGROUND: Type 2 diabetes mellitus (T2DM) approximately constitutes 90% of the 
      reported cases. 30-40% of diabetics eventually develop diabetic nephropathy (DN); 
      accounting for one of the major causes of morbidity and mortality. Increased 
      glucose autoxidation and non-enzymatic glycation of proteins in diabetic kidneys 
      lead to the excessive generation of reactive oxygen species (ROS) that results in 
      lipid peroxidation and activation of inflammatory mediators which overwhelms the 
      scavenging capacity of the antioxidant defense system (Nrf2/Keap1/HO-1). 
      Centratherum anthelminticum commonly called as kali zeeri (bitter cumin) and its 
      seeds are well known for culinary purposes in Asia (Pakistan). It has reported 
      anti-inflammatory, antioxidant, and anti-diabetic activities. The present study 
      has attempted to explore the in-vivo anti-inflammatory, antioxidant and 
      antihyperglycemic potential of the C. anthelminticum seed's fixed oil (FO) and 
      its fractions in high fat-high fructose-streptozotocin (HF-HFr-STZ) induced T2DM 
      rat model. METHODS: The T2DM rat model was developed by giving a high-fat and 
      high-fructose diet followed by a single intraperitoneal injection of 
      streptozotocin (STZ 60 mg/kg) on 28th day of the trial. After 72 hours of this 
      injection, rats showing fasting blood glucose (FBG) levels>/=230 mg/dL were 
      recruited into six groups. These groups were orally administered distilled water 
      (1 mL/kg), Gliclazide (200 mg/kg), Centratherum anthelminticum seed (FO) and its 
      hexane (HF), chloroform (CF) and ethanol (EF) soluble fractions (200 mg/kg each), 
      respectively for 4 weeks (i.e. 28 days). Blood, serum, and kidney tissue samples 
      of euthanized animals were used for biochemical, pro-inflammatory, and 
      antioxidant markers (ELISA, qRT-PCR, and spectrophotometric assays) and 
      histology, respectively. RESULTS: C. anthelminticum FO and its fractions reduced 
      the lipid peroxidation, and improved the antioxidant parameters: enzymatic (SOD, 
      CAT, and GPx), non-enzymatic (GSH), and mRNA expression of anti-inflammatory 
      markers (Nrf-2, keap1, and HO-1). mRNA expression of inflammatory and apoptotic 
      markers (TNF-alpha, IL-1beta, COX-1, NF-kappaB, Bax, and Bcl-2) were attenuated along with 
      improved kidney architecture. CONCLUSION: C. anthelminticum can mitigate 
      inflammation and oxidative stress in early DN. The anti-nephropathic effect can 
      be attributed to its ability to down-regulate NF-kappaB and by bringing the Nrf-2 
      expression levels to near normal.
CI  - (c) 2022. The Author(s).
FAU - Baig, Nida
AU  - Baig N
AD  - Clinical Laboratory Sciences, Institute of Medical Technology, Dow University of 
      Health Sciences, OJHA Campus, Karachi, Pakistan. nida.baig@duhs.edu.pk.
AD  - Department of Biochemistry, University of Karachi, Karachi, Pakistan. 
      nida.baig@duhs.edu.pk.
FAU - Sultan, Rabia
AU  - Sultan R
AD  - Dr. Panjwani Center for Molecular Medicine and Drug Research, International 
      Center for Chemical and Biological Sciences (ICCBS), University of Karachi, 
      75270, Karachi, Pakistan.
FAU - Qureshi, Shamim Akhtar
AU  - Qureshi SA
AD  - Department of Biochemistry, University of Karachi, Karachi, Pakistan.
LA  - eng
PT  - Clinical Trial, Veterinary
PT  - Journal Article
DEP - 20221118
PL  - England
TA  - BMC Complement Med Ther
JT  - BMC complementary medicine and therapies
JID - 101761232
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Antioxidants)
RN  - 30237-26-4 (Fructose)
RN  - 0 (Kelch-Like ECH-Associated Protein 1)
RN  - 0 (NF-E2-Related Factor 2)
RN  - 0 (NF-kappa B)
RN  - 0 (Plant Oils)
RN  - 0 (RNA, Messenger)
RN  - 5W494URQ81 (Streptozocin)
SB  - IM
MH  - Animals
MH  - Rats
MH  - Anti-Inflammatory Agents/pharmacology
MH  - Antioxidants/pharmacology/therapeutic use
MH  - *Asteraceae
MH  - *Diabetes Mellitus, Experimental/drug therapy
MH  - *Diabetes Mellitus, Type 2/drug therapy/complications
MH  - *Diabetic Nephropathies/drug therapy
MH  - Fructose
MH  - Kelch-Like ECH-Associated Protein 1/metabolism
MH  - NF-E2-Related Factor 2/metabolism
MH  - NF-kappa B/metabolism
MH  - Plant Oils
MH  - RNA, Messenger
MH  - Seeds
MH  - Streptozocin/therapeutic use
PMC - PMC9675141
OTO - NOTNLM
OT  - Centratherum anthelminticum
OT  - Diabetes mellitus
OT  - Fixed oil
OT  - NF-kappaB
OT  - Nephropathy
OT  - Nrf-2/Keap1/HO-1
COIS- None
EDAT- 2022/11/20 06:00
MHDA- 2022/11/23 06:00
PMCR- 2022/11/18
CRDT- 2022/11/19 00:10
PHST- 2022/03/15 00:00 [received]
PHST- 2022/09/28 00:00 [accepted]
PHST- 2022/11/19 00:10 [entrez]
PHST- 2022/11/20 06:00 [pubmed]
PHST- 2022/11/23 06:00 [medline]
PHST- 2022/11/18 00:00 [pmc-release]
AID - 10.1186/s12906-022-03776-x [pii]
AID - 3776 [pii]
AID - 10.1186/s12906-022-03776-x [doi]
PST - epublish
SO  - BMC Complement Med Ther. 2022 Nov 18;22(1):301. doi: 10.1186/s12906-022-03776-x.